Merck & Co Inc is to acquire VelosBio Inc for $2.75 billion in cash giving it ownership of an early clinical stage antibody-drug conjugate (ADC) targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1). The drug, VLS-101, is being evaluated in Phase 1 and Phase 2 clinical trials for the treatment of patients respectively, with haematologic malignancies and solid tumours.
